Nanocarriers can be useful tools for delivering drugs to the central nervous system (CNS). Their distribution within the brain and their interaction with CNS cells must be assessed accurately before they can be proposed for therapeutic use. In this paper, we investigated these issues by employing poly-lactide-co-glycolide nanoparticles (NPs) specifically engineered with a glycopeptide (g7) conferring to NPs the ability to cross the blood brain barrier (BBB) at a concentration of up to 10% of the injected dose. g7-NPs display increased in vitro uptake in neurons and glial cells. Our results show that in vivo administration of g7-NPs leads to a region- and cell type-specific enrichment of NPs within the brain. We provide evidence that g7-NPs are endocytosed in a clathrin-dependent manner and transported into a specific subset of early endosomes positive for Rab5 in vitro and in vivo. The differential Rab5 expression level is strictly correlated with the amount of g7-NP accumulation. These findings show that g7-NPs can cross the BBB and target specific brain cell populations, suggesting that these NPs can be promising carriers for the treatment of neuropsychiatric and neurodegenerative diseases.

Insight on the fate of CNS-targeted nanoparticles. Part I: Rab5-dependent cell-specific uptake and distribution / Vilella, Antonietta; Tosi, Giovanni; Andreas M., Grabrucker; Ruozi, Barbara; Belletti, Daniela; Vandelli, Maria Angela; Tobias M., Boeckers; Forni, Flavio; Zoli, Michele. - In: JOURNAL OF CONTROLLED RELEASE. - ISSN 0168-3659. - STAMPA. - 174:(2014), pp. 195-201. [10.1016/j.jconrel.2013.11.023]

Insight on the fate of CNS-targeted nanoparticles. Part I: Rab5-dependent cell-specific uptake and distribution

VILELLA, ANTONIETTA;TOSI, Giovanni;RUOZI, Barbara;BELLETTI, Daniela;VANDELLI, Maria Angela;FORNI, Flavio;ZOLI, Michele
2014

Abstract

Nanocarriers can be useful tools for delivering drugs to the central nervous system (CNS). Their distribution within the brain and their interaction with CNS cells must be assessed accurately before they can be proposed for therapeutic use. In this paper, we investigated these issues by employing poly-lactide-co-glycolide nanoparticles (NPs) specifically engineered with a glycopeptide (g7) conferring to NPs the ability to cross the blood brain barrier (BBB) at a concentration of up to 10% of the injected dose. g7-NPs display increased in vitro uptake in neurons and glial cells. Our results show that in vivo administration of g7-NPs leads to a region- and cell type-specific enrichment of NPs within the brain. We provide evidence that g7-NPs are endocytosed in a clathrin-dependent manner and transported into a specific subset of early endosomes positive for Rab5 in vitro and in vivo. The differential Rab5 expression level is strictly correlated with the amount of g7-NP accumulation. These findings show that g7-NPs can cross the BBB and target specific brain cell populations, suggesting that these NPs can be promising carriers for the treatment of neuropsychiatric and neurodegenerative diseases.
dic-2013
174
195
201
Insight on the fate of CNS-targeted nanoparticles. Part I: Rab5-dependent cell-specific uptake and distribution / Vilella, Antonietta; Tosi, Giovanni; Andreas M., Grabrucker; Ruozi, Barbara; Belletti, Daniela; Vandelli, Maria Angela; Tobias M., Boeckers; Forni, Flavio; Zoli, Michele. - In: JOURNAL OF CONTROLLED RELEASE. - ISSN 0168-3659. - STAMPA. - 174:(2014), pp. 195-201. [10.1016/j.jconrel.2013.11.023]
Vilella, Antonietta; Tosi, Giovanni; Andreas M., Grabrucker; Ruozi, Barbara; Belletti, Daniela; Vandelli, Maria Angela; Tobias M., Boeckers; Forni, Flavio; Zoli, Michele
File in questo prodotto:
File Dimensione Formato  
Vilella et al., JCR 2014, 174, 195-201.pdf

non disponibili

Tipologia: Post-print dell'autore (bozza post referaggio)
Dimensione 1 MB
Formato Adobe PDF
1 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/994516
Citazioni
  • ???jsp.display-item.citation.pmc??? 18
  • Scopus 55
  • ???jsp.display-item.citation.isi??? 46
social impact